U.S. FDA accepts Novo Nordisk's application for oral Wegovy
RefinitivLess than 1 min read
The U.S. Food and Drug Administration has accepted Novo Nordisk's 
NOVO_B marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news